TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

F. Demichelis; K. Fall; S. Perner; O. Andrén; F. Schmidt; S. R. Setlur; Y. Hoshida; J. M. Mosquera; Y. Pawitan; C. Lee; H. O. Adami; L. A. Mucci; P. W. Kantoff; S. O. Andersson; A. M. Chinnaiyan; J. E. Johansson; M. A. Rubin

doi:10.1038/sj.onc.1210237

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

F. Demichelis, K. Fall, S. Perner, O. Andrén, F. Schmidt, S. R. Setlur, Y. Hoshida, J. M. Mosquera, Y. Pawitan, C. Lee, H. O. Adami, L. A. Mucci, P. W. Kantoff, S. O. Andersson, A. M. Chinnaiyan, J. E. Johansson, M. A. Rubin

Research output: Contribution to journal › Article › peer-review

554 Scopus citations

Abstract

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

Original language	English (US)
Pages (from-to)	4596-4599
Number of pages	4
Journal	Oncogene
Volume	26
Issue number	31
DOIs	https://doi.org/10.1038/sj.onc.1210237
State	Published - Jul 5 2007
Externally published	Yes

Keywords

Cancer-specific death
ERG
ETS
Prognosis
Prostate cancer
TMPRSS2

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/sj.onc.1210237

Cite this

Demichelis, F., Fall, K., Perner, S., Andrén, O., Schmidt, F., Setlur, S. R., Hoshida, Y., Mosquera, J. M., Pawitan, Y., Lee, C., Adami, H. O., Mucci, L. A., Kantoff, P. W., Andersson, S. O., Chinnaiyan, A. M., Johansson, J. E., & Rubin, M. A. (2007). TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26(31), 4596-4599. https://doi.org/10.1038/sj.onc.1210237

Demichelis, F, Fall, K, Perner, S, Andrén, O, Schmidt, F, Setlur, SR, Hoshida, Y, Mosquera, JM, Pawitan, Y, Lee, C, Adami, HO, Mucci, LA, Kantoff, PW, Andersson, SO, Chinnaiyan, AM, Johansson, JE & Rubin, MA 2007, 'TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort', Oncogene, vol. 26, no. 31, pp. 4596-4599. https://doi.org/10.1038/sj.onc.1210237

@article{8a3af48abcc84d9987b4f9a72d93569b,

title = "TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort",

abstract = "The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.",

keywords = "Cancer-specific death, ERG, ETS, Prognosis, Prostate cancer, TMPRSS2",

author = "F. Demichelis and K. Fall and S. Perner and O. Andr{\'e}n and F. Schmidt and Setlur, {S. R.} and Y. Hoshida and Mosquera, {J. M.} and Y. Pawitan and C. Lee and Adami, {H. O.} and Mucci, {L. A.} and Kantoff, {P. W.} and Andersson, {S. O.} and Chinnaiyan, {A. M.} and Johansson, {J. E.} and Rubin, {M. A.}",

year = "2007",

month = jul,

day = "5",

doi = "10.1038/sj.onc.1210237",

language = "English (US)",

volume = "26",

pages = "4596--4599",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "31",

}

TY - JOUR

T1 - TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

AU - Demichelis, F.

AU - Fall, K.

AU - Perner, S.

AU - Andrén, O.

AU - Schmidt, F.

AU - Setlur, S. R.

AU - Hoshida, Y.

AU - Mosquera, J. M.

AU - Pawitan, Y.

AU - Lee, C.

AU - Adami, H. O.

AU - Mucci, L. A.

AU - Kantoff, P. W.

AU - Andersson, S. O.

AU - Chinnaiyan, A. M.

AU - Johansson, J. E.

AU - Rubin, M. A.

PY - 2007/7/5

Y1 - 2007/7/5

N2 - The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

AB - The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

KW - Cancer-specific death

KW - ERG

KW - ETS

KW - Prognosis

KW - Prostate cancer

KW - TMPRSS2

UR - http://www.scopus.com/inward/record.url?scp=34248510706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248510706&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210237

DO - 10.1038/sj.onc.1210237

M3 - Article

C2 - 17237811

AN - SCOPUS:34248510706

SN - 0950-9232

VL - 26

SP - 4596

EP - 4599

JO - Oncogene

JF - Oncogene

IS - 31

ER -

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this